Heterozygous familial hypercholesterolemia: individualized low-density lipoprotein cholesterol reduction with Alirocumab titration strategy


Patients with heterozygous familial hypercholesterolemia ( HeFH ) who completed the double-blind ODYSSEY LONG TERM parent trial and subsequently enrolled in the open-label extension ( OLE ) study, ODYSSEY OLE, provide a unique opportunity to investigate effects of two doses of Alirocumab ( Praluent ), a proprotein convertase subtilisin/kexin type 9 inhibitor, within the same patient cohort.

The aim of the study was to characterize long-term efficacy and safety of two Alirocumab dosages and utility of a dose titration strategy in patients with HeFH.

After an 8-week washout period, patients with HeFH who completed the LONG TERM study ( receiving Alirocumab 150 mg every 2 weeks [ Q2W ] ) were eligible to enroll in OLE ( n = 214 ) for up to 40 months' treatment duration.
In OLE, patients started on Alirocumab 75 mg Q2W.
From Week 12, dose adjustment from 75 to 150 mg Q2W or vice versa was possible based on physician's clinical judgment.

During the LONG TERM trial, Alirocumab 150 mg Q2W has reduced mean low-density lipoprotein cholesterol ( LDL-C ) from baseline ( 162.3 mg/dL ) to Week 8 by 63.1%; during OLE, Alirocumab 75 mg Q2W has reduced mean LDL-C from baseline ( 166.6 mg/dL ) by 47.3% within the same patient cohort.

At Week 96, mean LDL-C reduction from OLE baseline was 55.4% vs 46.8% for patients with or without Alirocumab dose increase, respectively.

Treatment-emergent adverse events leading to permanent treatment discontinuation were observed in 4 patients ( 1.9% ).

In conclusion, in patients with heterozygous familial hypercholesterolemia, both Alirocumab dosages provided consistent LDL-C reductions over a treatment duration of up to 4 years ( including 1.5 years of the LONG TERM trial ), allowing an individualized approach to LDL-C lowering, depending on baseline LDL-C levels. ( Xagena )

Dufour R et al, J Clin Lipidol 2018; Epub ahead of print

XagenaMedicine_2018



Indietro

Altri articoli

The ODYSSEY OUTCOMES ( Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab ) trial compared...


The European Commission ( EC ) has approved a new indication for Praluent ( Alirocumab ), to reduce cardiovascular (...


The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...


In statin trials, men and women have shown similar relative risk reductions in cardiovascular events per 39 mg/dL low-density lipoprotein...


ODYSSEY OLE ( open-label extension ) has included patients diagnosed with heterozygous familial hypercholesterolemia ( HeFH ), receiving maximally tolerated...


Positive results from the phase 3 ODYSSEY ESCAPE trial evaluating Alirocumab ( Praluent ) injection in patients with an inherited...


A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin...


Two anti-proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) monoclonal antibodies, Alirocumab and Evolocumab, have been approved for the treatment...


The 18-month ( 78-week ) results of a phase 3 trial of Alirocumab ( Praluent ), an investigational therapy, involving...